Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of ticagrelor 90 mg tablet versus BRILINTA 90 mg tablet in healthy Thai volunteers under fasting conditions
TCTR20260429008Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on TCTR20260429008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260429008.